CONTRACT FOR CARE · RIGHTS, CONSENT & GOVERNMENT POWER
Our Legal Case
A patient’s need for medicine should not become the pressure used to obtain a criminal admission. Examine compulsory disclosures, penalties for silence, coerced rights waivers, and the circumstances behind the signature.
Use the original agreement and policy sources for this record to identify the exact clause, its legal source, and the stated consequence. Preserve those facts before reaching a conclusion about a particular provider or condition.
Apply the constitutional and consent review to this record
- Government responsibility: Which law, binding rule, agency instruction, or public-provider policy requires the particular disclosure or consequence? Separate it from provider-added terms.
- Potential criminal admission: Identify the exact spoken answer, written history, certification, or explanation and the real criminal risk it creates.
- Penalty for silence: Record what happens if the patient invokes the privilege or refuses a rights waiver, including denial, discharge, or interruption of treatment.
- Consent and pressure: Preserve the circumstances of signing, severity of pain, accessible alternatives, and whether the patient could honestly accept the prospective obligations.
- Criminal-use protection: Identify legally sufficient immunity and limits on use of both the answer and evidence derived from it. A privacy assurance is a separate protection.
Read the precedents, evidence framework, clause review, and remedies and reform demands. The work develops a proposed constitutional challenge; applying it to a particular condition requires its facts and legal authority.
RHODE ISLAND · CONTRACT FOR CARE · DOCUMENT EVIDENCE
Maria Guglielmo / LPG Neurosurgery — 2019 Pain Management Agreement
Publicly hosted institutional PDF identifies Maria Guglielmo, MD, LPG Neurosurgery, East Greenwich, 1351 South County Trail. Her current institutional profile identifies Newport. A 2024-05 upload path is not a revision/effective date. Current use, distribution and office applicability are unconfirmed; this is not a system-wide Brown agreement.
Version evidence: Printed revised 2/21/2019.
Read the complete original document · Current institutional provider profile
State requirements and practice choices
The binding rule requires a signed written agreement in covered chronic-pain opioid treatment by 90 days (§4.4(F)); many possible clauses are discretionary. Patient education (§D), review (§G), and safe transition (§J) are separate duties. The 2026 statutory layer applies to its specified conditions. Scope and interaction with the regulation need individual review.
Source-located clause summaries
These are condensed paraphrases. Open the original for complete wording and context; page numbers count PDF pages. Classification identifies the source of a condition, not its enforceability.
| Location | Document requirement / consequence | Classification | Authority comparison |
|---|---|---|---|
| p1, opening consequence | Violation: prescribing stops immediately or after rapid taper; treatment program may be recommended. | Unresolved / legal review | G permits clinical consideration of discontinuation; J safe transition must be assessed separately. |
| p1, patient commitments | Communicate pain, function and medication effect. | Authorized / contemplated; discretionary | Treatment-plan and periodic-review subjects align with the regulation. |
| p1, substances | No illegal controlled substances and no alcohol on opioids. | Authorized / contemplated; discretionary | F(1)(d) contemplates substance conditions; exact abstinence implementation remains discretionary. |
| p1, sharing/prescriber | No sharing/sale/trade or obtaining opioids from another provider. | Authorized / contemplated; discretionary | F(1)(c) contemplates prescriber limitation. |
| p1, loss/refill | No replacement for loss/theft; office-hours refills only; none by phone. | Authorized / contemplated; discretionary | F(1)(a) contemplates protocols; specific limits are practice choices. |
| p1, authorizations | Pharmacy/law-enforcement cooperation and waiver of privacy/confidentiality privilege. | Unresolved / legal review | No matching blanket confidentiality waiver found in agreement rule; separate legal review. |
| p1, monitoring | Blood/urine tests on request; unused pain medicines at every visit. | Authorized / contemplated; discretionary | F(1)(f) contemplates testing; bringing medicine is a separate implementation. |
| p1, dose | Excess use leaves patient without medicine for a period. | Authorized / contemplated; discretionary | Record states consequence; actual clinical implementation unknown. |
Selected exact wording: “either immediately or after a rapid taper” (p1).
Refusal, noncompliance and continuity
Only consequences written in the located document are reported here. Actual enforcement and accommodations have not been independently established. These sources do not establish a separate consequence merely for refusing to sign. RIDOH’s June 10, 2015 guidance discusses context, clinical judgment and continuity; guidance and current binding rules remain separately labeled.
Update this evidence
Please identify current office use, replacement versions, exceptions and any factual correction. Privacy-waiver scope, dismissal and rapid taper language remain open for owner/legal review. No allegation of unlawful conduct or motive is made.
Rhode Island directory · Legal evidence library · Methodology
Reviewed: October 12, 2026.